VIVUS (VVUS) Said EQUIP and CONQUER Studies Met All Primary Endpoints
Up)
VIVUS, Inc. (Nasdaq: VVUS) announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa, an investigational drug, in more than 3,750 patients across 93 sites.
The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo. Patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and type 2 diabetes.
Highlights from the EQUIP and CONQUER studies include:
The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo. Patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and type 2 diabetes.
Highlights from the EQUIP and CONQUER studies include:
- Average weight loss of 14.7% (37 lbs) was achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
- Significant improvements in cardiovascular, metabolic and inflammatory risk factors among patients treated with Qnexa;
- FDA efficacy benchmarks for weight loss agents exceeded at all three doses of Qnexa tested in the clinical program;
- Completion rates up to 69% were significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability; and
- Favorable benefit/risk safety profile for Qnexa.
You May Also Be Interested In
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- Bernstein Sees VMware (VMW) Multiple Contraction If Slowdown in Virtualization Market Continues
- SodaStream (SODA) Shares Volatile as Exec Says Co. Received Approval to Sell Products in Brazil
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
